Pharmacyclics LLC, et al. v. Fresenius Kabi USA LLC, et al.

Analysis Group was retained by Covington & Burling on behalf of AbbVie and its affiliate Pharmacyclics, plaintiffs in a patent infringement litigation brought against manufacturers of a generic treatment for certain types of lymphomas and other diseases. AbbVie and Pharmacyclics partnered with co-plaintiff Janssen to develop Imbruvica (ibrutinib), an oral oncology drug. Subsequently, a number of defendants filed Abbreviated New Drug Applications (ANDAs) with the US Food and Drug Administration (FDA) to manufacture and sell generic versions of Imbruvica.

An Analysis Group team led by Principal Brian Ellman, Managing Principal Divya Mathur, and Vice President Devin Reilly supported President Pierre Cremieux who filed an expert report and testified regarding the commercial success of Imbruvica. Dr. Cremieux also rebutted the reports of opposing experts. 

In his ruling, a judge in the US District Court for the District of Delaware held that all four patents in the case were not shown to be invalid, noting that “[e]vidence adduced at trial demonstrates that Imbruvica® tablets and capsules are a commercial success.”